# A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

> **NCT06094296** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 1 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** BMS-986315
- **DRUG:** Nivolumab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06094296
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-27
- **Primary completion:** 2024-08-08
- **Final completion:** 2024-08-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094296, "A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06094296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*